Allena Pharmaceuticals is focused on treating complex metabolic conditions that can lead to significant and costly health complications. The Company aims to reduce the burden of toxic metabolites such as oxalate and uric acid. These metabolites are normal byproducts of cellular activity and are also derived from the typical diet. In certain circumstances, they can build up and lead to complications such as hyperoxaluria and kidney stones (nephrolithiasis) in the case of oxalate, or hyperuricemia and gout in the case of uric acid.

Employee Rating

0More
TypePrivate
HQNewton, US
Founded2010
Size (employees)48 (est)+5%
Websiteallenapharma.com
Allena Pharmaceuticals was founded in 2010 and is headquartered in Newton, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Allena Pharmaceuticals

Alexey Margolin

Alexey Margolin

CEO
Hugh Wight

Hugh Wight

Vice President of Technical Operations
Show more

Allena Pharmaceuticals Office Locations

Allena Pharmaceuticals has an office in Newton
Newton, US (HQ)
One Newton Executive Park, Suite 202
Show all (1)
Report incorrect company information

Allena Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

2010

Allena Pharmaceuticals total Funding

$93 m

Allena Pharmaceuticals latest funding size

$53 m

Time since last funding

3 years ago

Allena Pharmaceuticals investors

Allena Pharmaceuticals's latest funding round in December 2015 was reported to be $53 m. In total, Allena Pharmaceuticals has raised $93 m
View all funding rounds

Allena Pharmaceuticals Revenue

USD

Net income (Q2, 2018)

(16.5m)

EBIT (Q2, 2018)

(16.1m)

Cash (30-Jun-2018)

78.9m
Annual
USDFY, 2017

General and administrative expense

5.4m

R&D expense

15.5m

Operating expense total

21.0m

Interest expense

443.0k
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018

General and administrative expense

1.4m2.0m4.3m

R&D expense

2.9m5.9m11.8m

Operating expense total

4.4m8.0m16.1m

EBIT

(4.4m)(8.0m)(16.1m)
Annual
USDFY, 2017

Cash

94.5m

Current Assets

96.0m

PP&E

127.0k

Total Assets

96.2m
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018

Cash

33.9m86.4m78.9m

Current Assets

34.5m87.3m79.8m

PP&E

134.0k128.0k204.0k

Total Assets

36.3m87.6m80.1m
Annual
USDFY, 2017

Net Income

(21.6m)

Depreciation and Amortization

73.0k

Accounts Payable

199.0k

Cash From Operating Activities

(21.1m)
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018

Net Income

(15.0m)(7.9m)(16.5m)

Depreciation and Amortization

53.0k19.0k27.0k

Accounts Payable

150.0k529.0k(726.0k)

Cash From Operating Activities

(14.2m)(6.9m)(14.9m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Allena Pharmaceuticals News and Updates

Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

-- Global Phase 3 URIROX-1™ Trial Ongoing; Expect to Initiate Second Phase 3 Study, URIROX-2™, in 2018  -- -- Presented Preclinical Proof-of-Concept Data on ALLN-346 at American College of Rheumatology (ACR/ARHP) Annual Meeting and New Data Characterizing Unmet Need in Enteric Hyperoxaluri…

Allena Pharmaceuticals to Present at Upcoming Investor Conferences in November

NEWTON, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today anno…

Allena Pharmaceuticals Highlights Ongoing Efforts to Address Rare and Severe Metabolic Disorders Affecting the Kidney with Presentations at Upcoming Medical Meetings

NEWTON, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today ann…

Allena Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference

NEWTON, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today ann…

Allena Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

- Enrolling Global Phase 3 URIROX-1™ Trial; Plan to Initiate URIROX-2™ in 2H18 -
Report incorrect company information

Allena Pharmaceuticals Blogs

Allena Pharmaceuticals to Present at Upcoming Investor Conferences in October

Allena Pharmaceuticals to Present at Upcoming Investor Conferences in October Content Import Tue, 09/25/2018 - 08:05 Allena Pharmaceuticals to Present at Upcoming Investor Conferences in October September 25, 2018 This release is a backfill from a News Wire …

Andrew A. F. Hack, M.D., Ph.D.

Andrew A. F. Hack, M.D., Ph.D. Derek.Colman@n… Fri, 08/10/2018 - 08:44 Chair of the Audit Committee Andrew A. F. Hack, M.D., Ph.D.

Matt Kaplan

Matt Kaplan Derek.Colman@n… Thu, 08/02/2018 - 08:56 Matt Kaplan Ladenburg Thalmann

Allena Pharmaceuticals Announces First Patients Treated in Phase 2 Basket Study of ALLN-177 in Patients with Primary Hyperoxaluria or Enteric Hyperoxaluria and Advanced Chronic Kidney Disease

Allena Pharmaceuticals Announces First Patients Treated in Phase 2 Basket Study of ALLN-177 in Patients with Primary Hyperoxaluria or Enteric Hyperoxaluria and Advanced Chronic Kidney Disease Content Import Mon, 07/23/2018 - 08:03 Allena Pharmaceuticals Announces First Patients Treated in …

Allena Pharmaceuticals Company Life and Culture

Report incorrect company information

Allena Pharmaceuticals Frequently Asked Questions

  • When was Allena Pharmaceuticals founded?

    Allena Pharmaceuticals was founded in 2010.

  • Who are Allena Pharmaceuticals key executives?

    Allena Pharmaceuticals's key executives are Alexey Margolin and Hugh Wight.

  • How many employees does Allena Pharmaceuticals have?

    Allena Pharmaceuticals has 48 employees.

  • Who are Allena Pharmaceuticals competitors?

    Competitors of Allena Pharmaceuticals include MyoKardia, Athersys and Ironwood Pharmaceuticals.

  • Where is Allena Pharmaceuticals headquarters?

    Allena Pharmaceuticals headquarters is located at One Newton Executive Park, Suite 202, Newton.

  • Where are Allena Pharmaceuticals offices?

    Allena Pharmaceuticals has an office in Newton.

  • How many offices does Allena Pharmaceuticals have?

    Allena Pharmaceuticals has 1 office.